Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions

Journal of Immunology

Volumn 181, Issue 9, 2008, Pages 6664-6669

  Baudino, Lucie ^a   Shinohara, Yasuro ^b   Nimmerjahn, Falk ^c   Furukawa, Jun Ichi ^b   Nakata, Munehiro ^d   Martínez Soria, Eduardo ^a   Petry, Franz ^e   Ravetch, Jeffery V ^f   Nishimura, Shin Ichiro ^b   Izui, Shozo ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b HOKKAIDO UNIVERSITY   (Japan)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d TOKAI UNIVERSITY   (Japan)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; FC RECEPTOR; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; MONOCLONAL ANTIBODY; OLIGOSACCHARIDE; AUTOANTIBODY; IMMUNOGLOBULIN G; ISOPROTEIN; SIALIC ACID DERIVATIVE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BINDING AFFINITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; EFFECTOR CELL; EMBRYO; ERYTHROCYTE; GENE MUTATION; GENETIC VARIABILITY; MOUSE; MUTANT; MUTATION; NONHUMAN; PRIORITY JOURNAL; SIALYLATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; COMPLEMENT ACTIVATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ALANINE; AMINO ACID SUBSTITUTION; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIBODIES, MONOCLONAL; ASPARTIC ACID; AUTOANTIBODIES; COMPLEMENT ACTIVATION; ERYTHROCYTES; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FC; SIALIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58749100869     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.9.6664     Document Type: Article

References (30)

1. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity 24: 19-28. (Pubitemid 43077197)
2. Ravetch, J. V. 1994. Fc receptors: rubor redux. Cell 78: 553-560.
3. Klaus, G. G., M. B. Pepys, K. Kitajima, and B. A. Askonas. 1979. Activation of mouse complement by different classes of mouse antibody. Immunology 38: 687-695. (Pubitemid 10145294)
4. Azeredo da Silveira, S., S. Kikuchi, L. Fossati-Jimack, T. Moll, T. Saito, J. S. Verbeek, M. Botto, M. J. Walport, M. Carroll, and S. Izui. 2002. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J. Exp. Med. 195: 665-672.
5. Parekh, R. B., R. A. Dwek, B. J. Sutton, D. L. Fernandes, A. Leung, D. Stanworth, T. W. Rademacher, T. Mizuochi, T. Taniguchi, K. Matsuta, et al. 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316: 452-457.
6. Mizuochi, T., J. Hamako, M. Nose, and K. Titani. 1990. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J. Immunol. 145: 1794-1798. (Pubitemid 20336746)
7. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673. (Pubitemid 44201145)
8. Scallon, B. J., S. H. Tam, S. G. McCarthy, A. N. Cai, and T. S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44: 1524-1534.
9. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332: 738-740.
10. Duncan, A. R., J. M. Woof, L. J. Partridge, D. R. Burton, and G. Winter. 1988. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332: 563-564. (Pubitemid 18107928)
11. Baudino, L., F. Nimmerjahn, S. Azeredo da Silveira, E. Martinez-Soria, T. Saito, M. Carroll, J. V. Ravetch, J. S. Verbeek, and S. Izui. 2008. Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180: 1948-1953.
12. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446. (Pubitemid 30208162)
13. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51. (Pubitemid 41019656)
14. Lund, J., N. Takahashi, J. D. Pound, G. M., and R. Jefferis. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157: 4963-4969. (Pubitemid 126449574)
15. Park, S. Y., S. Ueda, H. Ohno, Y. Hamano, M. Tanaka, T. Shiratori, T. Yamazaki, H. Arase, N. Arase, A. Karasawa, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102: 1229-1238.
16. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. L. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92: 11490-11494.
17. Shibata, T., T. Berney, L. Reininger, Y. Chicheportiche, S. Ozaki, T. Shirai, and S. Izui. 1990. Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms. Int. Immunol. 2: 1133-1141.
18. Kuroki, A., Y. Kuroda, S. Kikuchi, F. Lajaunias, T. Fulpius, Y. Pastore, L. Fossati-Jimack, L. Reininger, T. Toda, M. Nakata, et al. 2002. Level of galactosylation determines cryoglobulin activity of murine IgG3 monoclonal rheumatoid factor. Blood 99: 2922-2928. (Pubitemid 34525382)
19. Fossati-Jimack, L., L. Reininger, Y. Chicheportiche, R. Clynes, J. V. Ravetch, T. Honjo, and S. Izui. 1999. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J. Exp. Med. 190: 1689-1696. (Pubitemid 30002350)
20. -/-) mice with wildtype bone marrow cells. J. Immunol. 167: 4033-4037.
21. Nishimura, S.-I., K. Niikura, M. Kurogochi, T. Matsushita, M. Fumoto, H. Hinou, R. Kamitani, H. Nakagawa, K. Deguchi, N. Miura, et al. 2004. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectrometry. Angew Chem. Int. Ed. Engl. 44: 91-96.
22. Furukawa, J. I., Y. Shinohara, H. Kuramoto, Y. Miura, H. Shimaoka, M. Kurogochi, M. Nakano, and S.-I. Nishimura. 2008. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal. Chem. 80: 1094-1101.
23. Kita, Y., Y. Miura, J. Furukawa, M. Nakano, Y. Shinohara, M. Ohno, A. Takimoto, and S.-I. Nishimura. 2007. Quantitative glycomics of human whole serum glycoproteins based on the standardized protocol for liberating N-glycans. Mol. Cell. Proteomics 6: 1437-1445. (Pubitemid 47365441)
24. Miura, Y., Y. Shinohara, J. Furukawa, N. Nagahori, and S. Nishimura. 2007. Rapid and simple solid-phase esterification of sialic acid residues for quantitative glycomics by mass spectrometry. Chemistry 13: 4797-4804. (Pubitemid 46910621)
25. Uematsu, R., J. Furukawa, H. Nakagawa, Y. Shinohara, K. Deguchi, K. Monde, and S.-I. Nishimura. 2005. High throughput quantitative glycomics and glycoform-focused proteomics of murine dermis and epidermis. Mol. Cell. Proteomics 4: 1977-1989. (Pubitemid 41830192)
26. 2,6-sialyltransferase. Biochem. Biophys. Res. Commun. 286: 243-249.
27. Molina, H., T. Miwa, L. Zhou, B. Hilliard, D. Mastellos, M. A. Maldonado, J. D. Lambris, and W. C. Song. 2002. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Blood 100: 4544-4549. (Pubitemid 35429696)
28. Anthony, R. M., F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, and J. V. Ravetch. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-376.
29. Nimmerjahn, F., and J. V. Ravetch. 2007. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204: 11-15. (Pubitemid 46148750)
30. Samuelsson, A., T. L. Towers, and J. V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory receptor. Science 291: 484-486. (Pubitemid 32097072)